Immuron (ASX:IMC) reported global sales for its immune supplement, Travelan, of roughly AU$2.5 million in the December 2024 quarter, a surge of 249% year on year, according to a Friday filing with the Australian bourse.

Sales in Australia soared 315% to nearly AU$1.9 million, while North American sales climbed 141% to AU$652,000.

Global half-year sales jumped 70% to AU$4 million.

The biopharmaceutical company's shares climbed past 8% in recent Friday trade.